GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN B) » Definitions » Float Percentage Of Total Shares Outstanding

H. Lundbeck AS (OCSE:HLUN B) Float Percentage Of Total Shares Outstanding : 0.00% (As of Dec. 12, 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, H. Lundbeck AS's float shares is 0.00 Mil. H. Lundbeck AS's total shares outstanding is 992.01 Mil. H. Lundbeck AS's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, H. Lundbeck AS's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, H. Lundbeck AS's Institutional Ownership is 11.79%.

H. Lundbeck AS Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

H. Lundbeck AS's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/992.01
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN B) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
OCSE:STENO ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA XSWX:SDZ NSE:DIVISLAB HKSE:03692 SZSE:000538 NSE:TORNTPHARM VTRS BOM:500124 BOM:532321 TSE:4507 BOM:543904 BOM:500257 NBIX
Traded in Other Exchanges
HLBBF:USA HLUBF:USA HLUNBc:UK 0ABR:UK 0ND5:UK HLUN A:Denmark LDBB:Germany LUNB:Austria
Address
Ottiliavej 9, Valby, DNK, 2500
Website
https://www.lundbeck.com
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS Headlines

No Headlines